Navigation Links
BioCis Pharma Reports Positive Phase IIa Clinical Results in Atopic Dermatitis
Date:7/3/2009

TURKU, Finland, July 3 /PRNewswire/ -- BioCis Pharma Ltd., a privately held drug development company with its headquarters in Turku, Finland, announced positive results from its Phase IIa clinical trial of ProtoCure(TM) emulsion cream, the company's novel topical drug for dermatology. This double-blind, placebo-controlled study, conducted in Finland, included 13 patients with mild to moderate atopic dermatitis who applied the ProtoCure emulsion cream to the affected skin areas twice daily for up to four weeks. The objectives were to evaluate the tolerability, pharmacokinetics, and efficacy of the topical treatment.

Study results showed excellent safety profile, and no serious adverse events were reported during the study. No patient dropped out due to adverse side effects of the treatment. Pharmacokinetic analyses showed no systemic exposure to the active ingredient of the product. Efficacy was assessed by performing instrumental measurements of skin lesion redness (erythema) and skin barrier function by trans-epidermal water loss (TEWL) during the 28-day period. Physician assessments, such as Eczema Area and Severity Index (EASI) were also evaluated. ProtoCure emulsion cream was superior to placebo in decreasing skin redness and improving skin barrier function. Statistically significant improvement was observed as early as day 10 after begining treatment. There was also a significant improvement in EASI score over the whole treatment period for ProtoCure emulsion cream as a sign of positive treatment effect. The EASI score difference did not reach statistical significance when compared to placebo, mainly due to the small number of patients studied.

"We are very pleased with the promising results of this study," says Lasse Leino, CEO of BioCis Pharma. "Skin barrier dysfunction is now recognized as a hallmark feature of atopic dermatitis. Any drug showing capacity for restoring this disturbance has signi
'/>"/>

SOURCE BioCis Pharma Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. BioCis Pharma Starts a Phase I Clinical Trial With a New Cancer Drug
2. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
3. King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use
4. Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints
5. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
6. Covance Announces Integrated Radiolabeled Clinical Pharmacology Studies
7. CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders
8. VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
9. Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009
10. Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)
11. DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Concord Medical Services Holdings Limited ("CCM" or the "Company") (NYSE: ... and operator of the largest network of radiotherapy and diagnostic ... that an Extraordinary General Meeting ("EGM") will be held on ... time) at CCM,s office at 18/F, Tower A, Global ... Beijing, P.R. China . Only ...
(Date:5/4/2015)... IRVING, Texas , May 4, 2015 /PRNewswire/ ... on fulfilling the promise of precision medicine, today ... center of excellence site in the Caris Centers ... has 10 hospitals in Maryland ... , region, and is a leader in oncology ...
(Date:5/4/2015)... May 4, 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or ... notification from the Food and Drug Administration ("FDA" or the ... March 31, 2015, has been placed on clinical hold pending ... related to the stability of the drug substance and drug ... The Company had sought approval of their IND application ...
Breaking Medicine Technology:Concord Medical Services Announces 2015 Extraordinary General Meeting of Shareholders 2Caris Life Sciences Designates MedStar Health a Caris Center of Excellence 2Caris Life Sciences Designates MedStar Health a Caris Center of Excellence 3ESSA Pharma Inc. Receives FDA Response on IND Application 2ESSA Pharma Inc. Receives FDA Response on IND Application 3ESSA Pharma Inc. Receives FDA Response on IND Application 4
... BOSTON, May 1, 2012 /PRNewswire-iReach/ -- ... healthcare Information Technology (IT) news and intelligence websites, ... in March.  The company also launched its first website, ... resource for electronic health record (EHR) news, intelligence, ...
... Calif., May 1, 2012  Ultragenyx Pharmaceutical Inc., a ... and ultra-rare genetic disorders, today announced results from ... in patients with hereditary inclusion body myopathy (HIBM) ... extended release profile on absorption after oral administration.  ...
Cached Medicine Technology:Xtelligent Media Raises $800K in Funding and Launches EHRintelligence.com 2Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease 2Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease 3
(Date:5/4/2015)... 04, 2015 World T.E.A.M. Sports’ best-attended ... ride in the last decade arrived in this historic ... in two days from the Pentagon in Arlington, Virginia. ... registered disabled and able-bodied participants work together to successfully ... and honors the commitment and sacrifices by military veterans ...
(Date:5/4/2015)... 04, 2015 “ Food Cost Calculator ” ... which takes a look at the latest and coolest applications ... the host of AppWatch and technology expert, conducted the app ... owners to manage and efficiently calculate food costs. , The ... In fact, the industry has an estimated 1.8 trillion dollar ...
(Date:5/4/2015)... 04, 2015 Peacock Alley knows ... He said, “My mother was the most beautiful woman I ... in lovely, feminine prints and textures to remind ... further than the Eloise Robe to get you there. The ... cap sleeve and tapered waist. It is available in small/medium ...
(Date:5/4/2015)... Sara Soulati, CEO of Global Cardio ... Los Angeles associated with the field of Enhanced External ... Sara Soulati Health For Life Program (SSHFLP). , The ... modification and disease prevention program. A provisional patent ... Patents and Trademarks Office and is now under review ...
(Date:5/3/2015)... May 03, 2015 Women’s Excellence ... Facebook page. , Their Facebook page consists ... services the Practice has, it’s multiple locations, Providers and ... Excellence has a very strong social media presence, with ... You Tube. , Women’s Excellence is the most ...
Breaking Medicine News(10 mins):Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 2Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 3Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 4Health News:An Application to Manage a Successful Restaurant Was Featured on NewsWatch Television 2Health News:Feminine Classics for Mother's Day Gifts from Peacock Alley 2Health News:CEO Sara Soulati Announces Patent-Pending Designation For The Sara Soulati Health For Life Program 2
... TV/Channel 7 and The,Detroit Department of Health and Wellness ... "boost" at the 31st annual "HEALTHY LIVING,FOR KIDS" program. ... 24,2008 from 10 a.m. to 5 p.m. at the ... inception in 1977, "Healthy Living for Kids",has provided free ...
... -- Tianyin,Pharmaceutical, Co., Inc. (OTC Bulletin Board: TYNP, ... medicine ("TCM") based in,Chengdu, China, today announced that ... OTC BB: TYNPE due to the electronic eligibility,system ... and the Company expects the,stock symbol to trade ...
... Fourteen physicians who have been,part of Commonwealth Medical ... and service they provide to their patients by joining ... and we are delighted they,have decided to join our ... officer. "We look forward to working with,them to support ...
... Aug. 20 Governor Edward,G. Rendell today said ... and a broken healthcare system, underscoring the need,to ... more,affordable for working adults., Nearly 900 guests ... & Industry Day Luncheon at Ag Progress Days, ...
... traitors, good cells gone bad. They evade the body,s defense ... , But researchers at the University of North Carolina at ... way to blow their cover. , Moo J. Cho, Ph.D., ... system that would embed bacterial elements in a cancer tumor ...
... found that infusions of a particular bone marrow stem ... in a mouse model. In their report published ... from the MGH Center for Engineering in Medicine report ... immune system activities, allowed the regeneration of the gastrointestinal ...
Cached Medicine News:Health News:WXYZ-TV/Channel 7 is 'On Your Side' With Healthy Living For Kids; Free Immunizations for Children on Sunday, August 24 at Charles H. Wright Museum of African American History 2Health News:WXYZ-TV/Channel 7 is 'On Your Side' With Healthy Living For Kids; Free Immunizations for Children on Sunday, August 24 at Charles H. Wright Museum of African American History 3Health News:Tianyin Pharmaceutical Co., Inc. Announces Trading Symbol Error and Correction 2Health News:Commonwealth Medical Group Physicians to Join Aurora Health Care 2Health News:Pennsylvania Governor Rendell Highlights Renewable Energy, Health Care Reform at Ag Progress Days 2Health News:UNC researcher aims to 'unmask' cancer cells to trigger body's immune system 2Health News:Bone marrow stem cells may help control inflammatory bowel disease 2Health News:Bone marrow stem cells may help control inflammatory bowel disease 3
... bed side and near patient testing is ... growth has posed unique problems for hospitals ... quality responsibility to decentralized areas focused on ... the problem is the reality of controlling ...
... The GenoSensor System includes genomic ... software, and reagents. By utilizing ... (CGH) technology for multi-target assessment, ... analyze multiple genomic targets in ...
... The CELL-DYN 3700 combines optical light ... Polarized Scatter Separation (MAPSS) to fully ... to improve performance and productivity in ... the revolutionary concept of complementary technologies ...
... Data Networking is hospital bedside glucose ... networking. In seconds, point of care ... from nursing stations throughout the hospital ... available to laboratory staff and the ...
Medicine Products: